Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T17:32:17.790Z.
Calculation as of: 2026-10-06T17:32:17.790Z.
Quote observation: 2026-10-06T17:28:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
TuHURA Biosciences, Inc.
Market Cap
$121.68M
Free Cash Flow Yield
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.68M | N/A |
| Cibus, Inc. (CBUS)vs › | $120.60M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.52M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.72M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.98M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.51M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.77M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.49M | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
